Letters Section Editor: Robert M. Golub, MD, Senior Editor.
To the Editor: Dr Campbell and colleagues1 conducted a systematic review of aspirin dose in prevention of cardiovascular disease. I believe that their use of the differences in bleeding rate observed in the post hoc analysis of the aspirin only group of the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial2 warrants clarification.
Clegg A. Aspirin Dose and Cardiovascular Disease Prevention. JAMA. 2007;298(6):625–626. doi:10.1001/jama.298.6.625-a